medigraphic.com

2003, Número 5

<< Anterior Siguiente >>

Rev Fac Med UNAM 2003; 46 (5)


Aerosolterapia mediante los nuevos inhaladores de dosis medida

Aviña FJA, Navarro IJE

Idioma: Español
Referencias bibliográficas: 18
Paginas: 190-192
Archivo PDF: 37.43 Kb.


RESUMEN

Los inhaladores de “dosis medida” que previamente dominaron el mercado de la aerosolterapia se han visto forzados a buscar nuevas tecnologías para evitar ser reemplazados por los dispositivos para “polvo seco” que se apropian progresivamente de la inhaloterapia. Se han reemplazado los compuestos propelentes clorofluorocarbonados (CFC) de la suspensión en spray, por los hidrofluoroalkanos que no son destructores de la capa atmosférica de ozono, surgiendo Evohaler y el Qvar que han añadido la característica de partículas respirables más pequeñas. Los nuevos modelos han incorporado mecanismos accionados por la respiración en los inhaladores Autohaler, Easi-Breathe y Xcelovent; y finalmente han conjuntado características de los dispositivos de polvo seco y ha surgido el reciente modelo híbrido Respimat.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Anderson PJ. Delivery options and devices for aerosolized therapeutics. Chest 2001; 120: 89-93.

  2. Roche N, Huchon GJ. Rationale for the choice of an aerosol delivery system. J Aerosol Med 2000; 13: 393-404.

  3. Weda M, Geuns ER, Vermeer RC et al. Equivalence testing and equivalence limits of Metered-dose inhalers and Dry powder inhalers measured by in vitro impaction. Eur J Pharm Biopharm 2000; 49: 295-302.

  4. Williams G. Moisture transport into chlorofluorocarbon-free Metered dose inhalers. J Allergy Clin Immunol 1999; 104: 227-229.

  5. Demedts M, Cohen R, Hawkinson R. Switch to non-CFC inhaled corticosteroids: a comparative efficacy study of HFA-BDP and CFC-BDP Metered-dose inhalers. Int J Clin Pract 1999; 53: 331-338.

  6. Davies R, Leach C, Lipworth B, Shaw R. Asthma management with HFA-BDP (QVAR). Hosp Med 1999; 60: 263-270.

  7. Vanden Burgt JA, Buss WW, Martin RJ, Szefler SJ, Donnell D. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol 2000; 106: 1209-1226.

  8. Cheng YS, Fu CS, Yazzie D, Zhou Y. Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica. J Aerosol Med 2001; 14(2): 255-66.

  9. Richards J, Hirst P, Pitcairn G, Mahashabde S, Abramowitz W, Nolting A, Newman SP. Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica. J Aerosol Med 2001; 14: 255-266.

  10. Donnell D. Inhaled corticosteroid delivery systems: clinical role of a breath-actuated device. Eur Rev Med Pharmacol Sci 2001; 5: 7-16.

  11. Worth H. Comparison of hydrofluoroalkane-beclomethasone dipropionate Autohaler with budesonide Turbuhaler in asthma control. Respiration 2001; 68: 517-526.

  12. Nolting A, Sista S, Abramowitz W. Single-dose study to compare the pharmacokinetics of HFA flunisolide and CFC flunisolide. J Pharm Sci 2002; 91: 424-432.

  13. Rydman RJ, Sonenthal K, Tadimeti L et al. Evaluating the Outcome of Two Teaching Methods of Breath Actuated Inhaler in an Inner City Asthma Clinic. J Med Syst 1999; 23: 349-355.

  14. Price DB, Pearce L, Powell SR et al. Handling and Acceptability Have the Easy-Breathe Device Compared With a Conventional Metered Dose Inhaler by Patients and Practice Nurses. Int J Clin Pract 1999; 53: 31-36.

  15. Busse WW et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999; 104: 1215-1222.

  16. Fireman P, Prenner BM, Vincken W, Demedts M, Mol SJ, Cohen RM. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol. Ann Allergy Asthma Immunol 2001; 86: 557-565.

  17. Newman S P, Joanne Brown, Karen P. Steed, Sandra J, Reader K, Heinrich Kladders. Lung deposition of Fenoterol and Flunisolide delivered using a novel device for inhaled medicines comparison of “Respimat” with conventional Metered-dose inhalers with and without spacer devices. Chest 1998; 113: 957-963.

  18. Goldberg J, Freund E, Beckers B, Hinzmann R. Improved delivery of fenoterol plus ipratropium bromide using Respimat compared with a conventional metered dose inhaler. Eur Respir J 2001; 17: 225-232.




2020     |     www.medigraphic.com